Astria Therapeutics Inc (209A.BE)
| Previous close | 0.0000 |
| YTD return | N/A |
| Expense ratio (net) | N/A |
| Category | N/A |
| Last cap gain | N/A |
| Morningstar rating | N/A |
| Morningstar risk rating | N/A |
| Sustainability rating | N/A |
| Net assets | N/A |
| Beta (5Y monthly) | N/A |
| Yield | N/A |
| 5y average return | N/A |
| Holdings turnover | N/A |
| Last dividend | N/A |
| Average for category | N/A |
| Inception date | N/A |
Business WireAstria Therapeutics to Present at Upcoming Global Angioedema Forum
BOSTON, September 27, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024.
Business WireAstria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
BOSTON, September 19, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Business WireAstria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, September 04, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria’s common stock on September 3, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
